Dechra Agrees to Acquire Gallant's Cell-Therapy Platform

The manufacturing facility in San Diego belongs inside the explanation of what Gallant has built. Its prospective buyer, Dechra, is agreeing to acquire a company that develops living-cell therapies and has assembled the capabilities to produce them, giving a veterinary specialty-care business another route into regenerative medicine.

The companies announced the acquisition agreement on November 9, 2026. Financial terms remain confidential, and completion is subject to customary closing conditions. Gallant's mesenchymal stromal cell, or MSC, therapies remain investigational, placing the commercial significance of this deal in the development organization and its future reach into veterinary practice.

What Dechra is agreeing to acquire

Gallant develops ready-to-use cell therapies for diseases in dogs and cats. Its current pipeline spans refractory feline chronic gingivostomatitis, a painful oral condition; osteoarthritis in both species; feline chronic kidney disease; and canine atopic dermatitis. The company says these products are investigational and unavailable for general use, although clinical-trial participation may provide access.

The intended treatment model uses donor-derived cells administered intravenously. That design gives the development program a practical destination: a veterinary team that needs to understand which patients might benefit and how a treatment would fit its clinical work. Demonstrating a useful therapy and making its administration manageable are connected commercial responsibilities.

Gallant's own acquisition announcement dates its founding to 2018 and describes its San Diego manufacturing facility as compliant with Good Manufacturing Practices. The site adds a tangible operating capability to a pipeline whose value still depends on clinical and regulatory progress. Dechra expressly ties the transaction to unmet needs in specialty care, without disclosing a purchase price or expected closing date.

For a biotech buyer, that combination invites a wider assessment than a list of disease targets. The people who understand a cell product, the processes used to produce it and the evidence behind its intended use all travel into the acquisition discussion. Neither company has published a detailed integration plan, so the future arrangement of those responsibilities remains open.

A veterinary development team with manufacturing experience

CEO Linda Black joined Gallant's founding team in 2019 and became CEO in April 2021. A veterinarian with a PhD in cell and molecular biology, she previously worked on veterinary stem-cell product development. Her background gives the company's ambition a clinical and commercial lineage beyond this week's transaction.

CTO Carolyn Wrightson brings experience in cell manufacturing and technical operations, while manufacturing-site head and COO Fareed Mohammed oversees the facility and manufacturing strategy. Gallant's team page describes work on commercial readiness, manufacturing capacity and quality. These are relevant capabilities for a cell-therapy business preparing to move its research toward routine veterinary care.

The financing behind that preparation is visible. Gallant announced an $18M Series B in June 2025 led by Digitalis Ventures, with BOLD Capital, Hill Creek Partners and NovaQuest Capital Management participating. The financing supported development and commercial preparation for its lead oral-disease program and broader pipeline. That historical round supplies context for the company Dechra has agreed to buy; it supplies no answer about the confidential acquisition price.

The pairing also brings different institutional experience into view. Jesper Nordengaard leads Dechra, whose business already serves veterinary professionals across multiple markets. If the transaction closes, Gallant's specialized development and manufacturing organization would sit within that larger veterinary business, with the division of future operating responsibilities still to be disclosed.

Clinical progress carries specific boundaries

Gallant's May 6 canine osteoarthritis update reported positive results from a randomized, placebo-controlled pilot study in 88 client-owned dogs. The company described 2 intravenous doses given 14 days apart, with follow-up through day 90. It also reported eligibility for the FDA's expanded conditional approval pathway and identified 2028 as its conditional-approval target.

Its April feline osteoarthritis announcement reported a separate pilot involving 35 cats across 6 U.S. veterinary clinics, along with eligibility for that pathway. These are company-reported development milestones. The species, study design and duration matter when interpreting the findings, and a pilot result cannot establish every claim a future marketed therapy might carry.

The FDA's explanation of conditional approval helps place those announcements. Conditional approval requires safety and a reasonable expectation of effectiveness, while full approval requires substantial evidence of effectiveness. Eligibility to use the pathway comes before an approval decision. Gallant's current investigational labeling is therefore the appropriate starting point for a reader assessing treatment availability today.

For Dechra, the proposed acquisition would bring responsibility for programs moving through that evidence-building process. For veterinarians and pet owners, the useful information will remain product-specific: the indication, evidence, regulatory status and permitted use of each therapy. The acquisition announcement gives no basis for replacing those questions with a blanket promise about regenerative medicine.

Dechra is building across biological approaches

Dechra has already made a relevant portfolio choice through Invetx, the companion-animal antibody developer it acquired in 2024. Invetx's platform develops monoclonal antibodies, while Gallant's programs use cells. Bringing both approaches into the same specialty-care organization would broaden the kinds of biological development Dechra can pursue around chronic animal disease.

The broader organization has also strengthened its U.S. presence. Dechra opened its global headquarters in Boston in June 2026, describing it as a collaboration hub for employees, customers, researchers and partners. Gallant's San Diego manufacturing capability would add a different function to that picture: the place where a cell-therapy development program must become a consistently produced product.

The operating work around veterinary innovation is appearing elsewhere in the sector. DevCuration's coverage of Familiar Therapeutics' veterinary drug-development model examines the organization needed to take research into animal medicines, while RxActuator's manufacturing and clinic-adoption plans follow the delivery of care into practice. The technologies differ, but the clinical setting keeps shaping what a commercial organization needs to build.

Gallant's route now points toward a buyer with established veterinary relationships and another biological platform already inside the business. Its scientists and manufacturing team continue to carry programs toward the clinic while the acquisition awaits completion, leaving Dechra's specialty-care ambition connected to the studies, production decisions and veterinary conversations still ahead.